Cabozantinib 60mg tablet ip

Cabozantinib 60mg (trade name Cabometyx and others) is an anti-cancer drug.

Class of Drug: Anti neoplastic CABOZANTINIB 60MG TABLET tyrosine kinase inhibitor (TKI).

Mechanism of Action: It inhibits specific receptor CABOZANTINIB 60MG TABLET IN PAKISTAN enzymes that support tumor growth (for example, VEGFR, MET, and AXL).

Physical Appearance: Normally formulated as film-coated tablets (yellow and oval in shape with markings “XL” and “60” on both sides).

Important Information: Capsules and tablets of cabozantinib are not bioequivalent and cannot be interchangeable.

Cabozantinib 60 mg is administered either as monotherapy or in combination for the treatment of.

Renal cell carcinoma (kidney cancer) alone or in combination with nivolumab.

Hepato cellular carcinoma (liver cancer) in patients who have failed other treatments (like sorafenib).

Advanced, progressive differentiated thyroid cancer (DTC)
Well-differentiated pancreatic and extra-pancreatic neuro endocrine tumors.

Usual Dosage: 60 mg per day administered orally as a mono therapy.

Taking with Food: The drug must be taken on an empty stomach—at least 1 hour before or 2 hours after a meal. It must be swallowed with water without being chewed or crushed.

Surgery Caution: Administration is suspended at least 3 weeks (or 28 days based on local recommendations) prior to surgery or dental procedure.